Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Total Debt (2020 - 2025)

Historic Total Debt for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to $13.5 million.

  • Rani Therapeutics Holdings' Total Debt fell 5217.45% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 5217.45%. This contributed to the annual value of $24.6 million for FY2024, which is 1622.82% down from last year.
  • Latest data reveals that Rani Therapeutics Holdings reported Total Debt of $13.5 million as of Q3 2025, which was down 5217.45% from $17.2 million recorded in Q2 2025.
  • Rani Therapeutics Holdings' Total Debt's 5-year high stood at $29.5 million during Q2 2024, with a 5-year trough of $30000.0 in Q2 2022.
  • For the 5-year period, Rani Therapeutics Holdings' Total Debt averaged around $18.2 million, with its median value being $22.8 million (2024).
  • Its Total Debt has fluctuated over the past 5 years, first crashed by 9922.76% in 2022, then skyrocketed by 9745000.0% in 2023.
  • Rani Therapeutics Holdings' Total Debt (Quarter) stood at $126000.0 in 2021, then soared by 23034.13% to $29.1 million in 2022, then increased by 0.8% to $29.4 million in 2023, then fell by 16.23% to $24.6 million in 2024, then plummeted by 45.0% to $13.5 million in 2025.
  • Its Total Debt was $13.5 million in Q3 2025, compared to $17.2 million in Q2 2025 and $20.9 million in Q1 2025.